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miRNAs are non coding ribonucleic acids which are protected with respect to evolution, and have a length of 18–
25 nucleotides. microRNAs control the gene expression after transcription, through mRNA destruction or translation
processing, and therefore participate in arrangement of the physiologic and pathologic cellular processes; They also
may act as oncogene or tumor suppressors. Altered expression of a number of microRNAs is reported in process of
progression and metastasis of thyroid cancers. Therefore, identification of these microRNAs may shed a light to
oncogenesis pathway of thyroid cancers and their metastasis. In addition, microRNAs might apply as potential
biological markers in diagnosis and treatment of thyroid cancers. The changes made in miRNAs profile of thyroid
cancers are reviewed in this paper.
Keywords: Thyroid Cancer, microRNA, Oncomir, FascinIntroduction
Despite the fact that thyroid malignances are ranked
14th among all kinds of cancers, and affect only 1- 2% of
all cancer sufferers, but they are considered as the most
prevalent cancer of the endocrinology system. The an-
nual occurrence of such cancer ranges from 0.5 to 10%
among 100000 persons in different parts of the world
[1-3]; women are believed to be 2–4 times more likely to
develop the condition [4]. Various studies show that
about 3-5% of the affected subjects have positive family
histories of the cancer [5,6]. In addition to the effect of
sex and genetic factors, the size of the body [7,8], race
[9], geographical distribution [10] and the amount of
iodine intake [11] affect the rate of developing thyroid
cancers. Thyroid malignances may break out at any age;
nevertheless, the majority of the cases are aged over 30.
It is specified that with aging, the invasion rate of such
cancers increase [2,12].
Pathological analysis of thyroid cancer demonstrates
that four types of the condition are more prevalent:
papillary, follicular, anaplastic and medullary thyroid* Correspondence: v.haghpanah@gmail.com
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reproduction in any medium, provided the orcarcinoma. The first three categories origin from follicular
cells, whereas medullary carcinoma derives from para-
follicular cells (C-cells) [3,13]. Recent studies conducted in
this field revealed that the gradual evolution of natural
cells to neoplastic ones in the process of tumor develop-
ment is the result of sequential genetic events, from
among which changes in miRNAs profile is the main focus
of the present study.miRNAs
In 1993, the first miRNA, also known as Lin-4 (Lineage-4),
was discovered in C. Elegans; it was, however, not earlier
than 2001 that Let-7 was discovered. At that time, the
importance of such molecules as a biological regulator
had not been determined [14].
Micro-RNAs (miRNAs) are single strand 18-25-
nucleotide RNAs, which are transcribed by RNA Poly-
merase II from miRNA genes. They are however not
translated into proteins. As the negative regulators of gene
expression, they bind to 3'UTR of the Target mRNA, and
prevent the translation process through destructing or
blocking the mRNA. miRNAs are non-encoder endogen-
ous RNAs, that apart from negative regulation of encoder
protein genes, regulate various cellular processes such as
reproduction, proliferation, difference, cell survival and
carcinogenesis mechanisms [15]. Mechanism of miRNAsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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siRNAs, although, they are completely different. It is esti-
mated that miRNA genes account for 2-5% of the human
genome [16]. Up to now, more than 1800 types of
miRNAs are recognized in plants, animals and even in
viruses. It is estimated that human’s genome includes 800
to 1000 miRNAs, most of which are only found in human
beings [17]. Most of the miRNAgenes, located within the
intron and exon of the encoding genes of various proteins
and may be transcribed the polycistron. For instance, miR-
221 and miR-222 are located on chromosome X and their
deregulated expression is shown in some carcinomas such
as thyroid cancer [18].
Approximately, each miRNA controls the expression
of more than 200 Genes. Many miRNAs have special
tissue expression, which may be higher or lower than
that of normal tissues [19]. In other words, altered
expression of certain miRNAs is linked with some can-
cers, including various kinds of thyroid cancer [18].
Although, the exact function of many miRNAs is not
well distinguished, many believe determination of im-
portant miRNAs in cancerous tissues may help improve
the understanding of the regulation of gene expression
in various types of cancer. Cancer occurs when the regu-
lation, proliferation and differentiation process is altered.
The cancers that are insensitive to growth stimulating
and suppressing signals, have unlimited proliferation and
angiogenesis potential, are preserved from apoptosis, es-
cape the immune system, have genome instability and me-
tastasis ability may become malignant [20-23] (Table 1).
Altered expression of miRNAs through decreased ex-
pression of certain genes involved in cell proliferation and
survival may result in cancer. This however does not sug-
gest that miRNAs are directly involved in tumorigenesis
and the development of cancer as the available studies
have failed to show whether altered expression of
mRNAs is the consequence of cancer or malignanciesTable 1 Role of miRNAs in the development of certain types o
Main characteristics of Cancer F
Insensitivity to stimulating and suppressing signals of growth ● Growth st
● Growth su
Escape from programmed cell death (Apoptosis) ● Apoptosis
● Apoptosis
Unlimited proliferation potential ● Immortalit
Angiogenesis induction ● Angiogen
● Angiogen
Escape from immune system ● Escape fro
Metastasis ● Metastasis
● Metastasis
Genome instability ● Genome iare secondary to altered expression. Nonetheless, cer-
tain changes that occur in cancerous cells can affect
miRNAs expression directly or indirectly [25].
In some types of cancers, such as thyroid neoplasia,
miRNAs are deregulated. Altered expression of miRNAs
plays an important role in tumorigenesis. Special subsets
of miRNAs in certain tumors have increased or reduced
expression. Increased expression of miRNAs may result in
reduced expression of tumor suppressor genes, and their
decreased expression may activate proto-oncogenes. The
number of genes, considered as the target of miRNAs and
involved in cancer, is increasing very fast [19]. For in-
stance, let-7 is a negative regulator of RAS [25], whereas
miR-221 and miR-222 are the negative regulators of KIT
Receptor [26]. CDKN1B, an important control factor in
cell cycle, is linked with cell development in S Phase of the
cycle) [27]. miR-16-1 and miR-15a may cause reduced
expression of BCL2, which is involved in apoptosis [28].
Such miRNAs, also known as oncomirs, are present in
various types of cancer. Their genes are located on the loci
on which deletion, duplication and point mutation has oc-
curred [29,30]. Some of microRNAs act through reducing
the expression of tumor suppressing genes, cell differenti-
ation regulatory genes and apoptosis. Others, on the other
hand, act through targeting proto-oncogenic mRNAs and
silencing such mRNAs, thus, lower the risk of these cells
becoming cancerous [31]. Altered expression of some
miRNAs may cause cells to become cancerous, affect
cell growth through interfering with the regulation of
cell cycle. miRNAs are the most important factors in
the regulation of programmed cell death during tumori-
genesis; the survival of cancerous cells, on the other
hand, are influenced by changing the expression of such
micro-RNAs.
Cancerous cells become immortal by protecting their
telomeres through positive regulation of telomerase and
telomere preservation. Any change in the expression off cancer [24]
unction miRNAs




y and aging control ● miR-290,-24,-34a
esis stimulation ● MiR-17-92Cluster,-378,-996,-27b,-130,-126,Let-7f
esis suppression ● miR-15,-16,-20a,-20b




nstability induction ● miR-16-1,-17,-20A,-15
Samimi et al. Journal of Diabetes & Metabolic Disorders 2013, 12:31 Page 3 of 5
http://www.jdmdonline.com/content/12/1/31miRNAs interferes with high-level telomerase activity in
tumors [32]. Deregulatory mechanisms of miRNAs in
tumor tissues are not completely determined [33,34].
Recently, adding other molecular markers such as
miRNAs to the mutant panels has improved the sensitivity
of cancer diagnosis. miRNAs are involved in the pathogen-
esis of certain cancers, such as thyroid neoplasia. Not
much is known about the clinical and pathological proper-
ties of the disease and expression of special miRNAs; how-
ever altered miRNA expression is reported in cancerous
thyroid tissues compared with healthy cells. In other
words, increased miRNA expression is reported in 32%
of thyroid malignances, whereas 38% of them present
reduced expression [35] (Table 2).
Such information suggests the role of deregulated
expression of miRNAs in the transformation of thyroid
cells. For instance, increased miR-187 expression is
reported in tumors with RET/PTC gene rearrangement,
whereas that of miR-221 and miR-22 is observed in
tumors positive for BRAF and RAS mutations as well as
papillary carcinomas with unclear mutation. Increased
miR-146b expression is seen in tumors with RAS muta-
tion. Such information can help facilitate detecting ma-
lignant tumors in FNA (Fine Needle Aspiration) samples
with high sensitivity even when molecular tests have
failed to report any mutations [35-40].
microRNAs in Epithelial Mesenchymal Transition
(EMT)
Metastasis is a complicated dynamic biological event,
subject to the separation of cancerous cells from adja-
cent tissue. Indeed, metastasis increases the risk of death
secondary to cancer. There are different special mecha-
nisms for the metastatic processin various cancerous
cells. Shifting the focus to the studies aiming to
recognize the reason behind the changes noted in the
expression of suppressor genes or metastasis activators
can pave the way to better understand different aspects
of such phenomenon, and thus develop effective ways to
prevent cancer. EMT is one of the most important way
of the metastatic process [41]. The miRNAs-200 family
islately considered as strong regulators of EMT, as they
affect the balance between EMT and MET its reversed
process [42]. This family consists of five members di-






Medullary Carcinoma miR-323,-370,-129,-137,-10a,-124a,-224,-127,-9,-154141 [43]. miRNA-200c regulates EMT through suppress-
ing ZEB1/2 (transcription suppressors of E-cadherin).
This miRNAcan suppress Bmi-1, which is a polycomb
protein responsible for the preservation of its essential
characteristics, in healthy and cancerous stem cells.
Recent studies confirm the role of miRNA-200c in the
regulation of EMT [44].
The invasion and metastasis of tumor cells is a major
cause of mortality in cancer patients. Fascin is another
protein involved in EMT process. Fascins are globular
proteins of approximately 55 kDa composed of four
tandem fascin domains, each of which corresponds
structurally to a β-trefoil fold. Fascin1, an actin-bundling
protein, has been demonstrated to be critical for filopodia
formation and thus is believed to be vital in movement
including and cell migration. The formation of such
structures is associated with increased risk of invasion
and metastasis [45]. Immunohistochemistry (IHC), tissue
microarray (TMA) study and qRT- PCR of various cancers
confirms increased expression of Fascin-1,especially in
metastatic lung and breast neoplasia [46]. miRNAs are
important factors involved in the regulation of fascin
expression rate. Different studies have revealed the role
of 145, 133a, 133b and miRNA-146a in increased ex-
pression of fascin [47].
Conclusion
More research is needed to clarify the regulatory mecha-
nisms of microRNAs and their role in the development of
thyroid cancers. The study of target microRNA molecules
along with their effects on signaling pathways and metas-
tasis may cause better understanding of such mechanisms.
Furthermore, microRNAs can pave the way for the devel-
opment of novel treatment modalities for thyroid cancers;
however, these options are associated with certain impedi-
ments and problems. For instance, microRNAs control
the expression of certain target genes; therefore, change in
any of such genes may target other genes rather than the
main ones. On the other hand, several microRNAs may
control a single gene by and thus, any change in the ex-
pression of even one of this microRNA may not be an ef-
fective treatment in this regard. Also, transfer of antisense
oligonucleotides for decreased expression of microRNAs,
which are involved in cancer, may affect non-targeted
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tioned facts, in order to benefit from microRNAs, increase
their usefulness, and minimize the undesirable effects aris-
ing from interconnection of antisense oligonucleotides to
the non-target microRNAs, further studies are needed.
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